Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 488 clinical trials
Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer

This is a prospective, single site, randomized, double-blind Phase III clinical trial to evaluate the clinical value of Traditional Chinese Medicine in the adjuvant therapy of triple-negative breast cancer patients.

triple-negative breast cancer
adjuvant therapy
platelet count
oestrogen receptor
immunohistochemistry
  • 0 views
  • 19 Feb, 2024
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

This is a open-labeled, single-arm, Investigator-initiated clinical trial of camrelizumab (an anti-PD-1 antibody) in combination with radiotherapy in patients with early triple-negative breast cancer. We will enroll 60 subjects. This study aims to evaluate the efficacy and safety of camrelizumab combined with radiotherapy in the treatment of early TNBC

triple-negative breast cancer
platelet count
lymphadenectomy
HER2
lymph node metastases
  • 0 views
  • 19 Feb, 2024
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: Sacituzumab govitecan (IMMU-132) Pembrolizumab (Keytruda; MK-3475)

cns disease
triple negative breast neoplasms
neuropathy
immunomodulators
keytruda
  • 8 views
  • 19 Feb, 2024
Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: Ipatasertib Atezolizumab

ipatasertib
colony stimulating factor
adjuvant therapy
platelet count
sentinel lymph node biopsy
  • 0 views
  • 19 Feb, 2024
Antler Plate on Preventing Mammary High-risk Lesions From Malignant Development

This study aims to prove whether antler disk extract can be put into clinical practice to prevent breast precancerous lesions from developing into cancer.

  • 0 views
  • 19 Feb, 2024
Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile

In this study investigators will perform cytokine profiling among patients diagnosed with metastatic triple-negative breast cancer at different time points during the treatment.

triple-negative breast cancer
multiple malignancies
breast cancer
cancer
metastatic breast cancer
  • 0 views
  • 19 Feb, 2024
Bringing of PET-TDM FDG in the Determination of the Characteristics of Primary Mammary Tumors TrIple Negatives

The investigator's goal is to characterize by innovative methods (anatomo-pathological in particular Of Immunohistochemistry, and morpho-functional imaging (TEP-TDM FDG) semi-quantitative and texture) in a population of Triple Negative Breast Cancer scans better knowledge of this entity that can lead to the development of relevant therapeutic strategies and especially more adapted …

triple-negative breast cancer
estrogen
immunohistochemistry
triple negative breast cancer
mastectomy
  • 0 views
  • 19 Feb, 2024
Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy

Neoadjuvant systemic therapy (NST) is increasingly recommended for patients with early breast cancer, and the rate of patients with pathological complete remission (pCR) is increasing due to the use of modern chemotherapy regimens and targeted therapies, especially in patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer …

  • 0 views
  • 19 Feb, 2024